ASH 2019 | Idasanutlin and venetoclax in elderly R/R AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents the updated results of the phase Ib study of the MDM2 inhibitor idasanutlin in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia (AML) who are ineligible for cytotoxic chemotherapy (NCT02670044). The rationale for this is that idasanutlin may help improve the response to venetoclax by promoting the degradation of MCL1 and enhancing the pro-apoptotic pathway. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up